ArticleCureus2025
Clinico-Biochemical Profiles and Outcomes in Acute Decompensated Heart Failure.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Acute decompensated heart failure (ADHF) is a major global health concern with rising prevalence in India, marked by earlier onset, high mortality, and frequent hospitalizations. This study aims to compare the risk factors, clinical and biochemical profiles, and in-hospital outcomes of ADHF patients with preserved versus reduced ejection fraction, addressing a key gap in Indian data. Materials and methods A cross-sectional observational study was conducted in the Department of Medicine at MM Institute of Medical Sciences and Research, Mullana, enrolling 100 consecutive patients aged ≥18 years with a confirmed diagnosis of heart failure according to the American College of Cardiology/American Heart Association/Heart Failure Society of America (2022 guidelines) (ACC/AHA/HFSA) 2022 definition. Patients with congenital heart disease, chronic cor pulmonale, or rheumatic heart disease were excluded. After informed consent, all participants underwent detailed history-taking, clinical examination, and investigations, and were followed until discharge or death. Data were analyzed using SPSS v26.0 with descriptive and inferential statistics, with p < 0.05 considered statistically significant. Results Overall, 52% of patients had heart failure with reduced ejection fraction (HFrEF) and 48% had heart failure with preserved ejection fraction (HFpEF), with a male predominance and a mean age of 62.3 years. Anemia and sepsis were common precipitating factors, while hypertension, obesity, and chronic obstructive pulmonary disease (COPD) were more associated with preserved ejection fraction (EF). In-hospital mortality was 10%. Elevated total leukocyte count (TLC), N-terminal pro-B-type natriuretic peptide (NT-proBNP), serum creatinine, and shock were significantly linked to poorer outcomes, with creatinine emerging as a strong predictor of mortality. Conclusion This study highlights the diverse clinico-biochemical profile of ADHF patients and the high prevalence of comorbidities. Significant differences were observed between preserved and reduced EF groups. Despite these variations, in-hospital mortality did not differ significantly, emphasizing the need for comprehensive risk assessment beyond ejection fraction to guide timely, individualized management in ADHF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.